Venture Visionary Partners LLC Has $4.27 Million Stock Holdings in Novo Nordisk A/S $NVO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Venture Visionary Partners LLC lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 1,568.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 61,499 shares of the company's stock after purchasing an additional 57,812 shares during the quarter. Venture Visionary Partners LLC's holdings in Novo Nordisk A/S were worth $4,270,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of NVO. Nuveen LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth $370,272,000. Nuveen Asset Management LLC boosted its stake in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after buying an additional 2,639,693 shares in the last quarter. Two Sigma Investments LP acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at about $158,657,000. Bank of America Corp DE boosted its stake in Novo Nordisk A/S by 8.1% in the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after buying an additional 1,165,955 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Novo Nordisk A/S by 26.8% in the fourth quarter. Northern Trust Corp now owns 4,689,098 shares of the company's stock valued at $403,356,000 after buying an additional 991,022 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. HSBC lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective on the stock. in a research note on Thursday, July 31st. Hsbc Global Res downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 31st. Barclays reiterated an "equal weight" rating on shares of Novo Nordisk A/S in a research report on Wednesday, July 30th. Finally, Wall Street Zen downgraded Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. One research analyst has rated the stock with a sell rating, twelve have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $83.75.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $53.81 on Tuesday. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company has a market capitalization of $240.26 billion, a price-to-earnings ratio of 14.78, a price-to-earnings-growth ratio of 1.80 and a beta of 0.63. The business has a 50-day moving average of $64.52 and a 200-day moving average of $70.02.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. The company had revenue of $11.69 billion during the quarter, compared to the consensus estimate of $77.51 billion. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is 45.05%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.